Anika Therapeutics Stock
Anika Therapeutics Stock
A very strong showing by Anika Therapeutics today, with an increase of €1.40 (10.530%) compared to yesterday's price.
Anika Therapeutics is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
On the other hand, the target price of 13 € is below the current price of 14.7 € for Anika Therapeutics, so the potential is actually -11.56%.
Our community identified positive and negative aspects for Anika Therapeutics stock for the coming years. 1 users see the criterium "Brand" as a plus for the Anika Therapeutics stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | 10.530% | 7.258% | 5.556% | 84.722% | 66.250% | -40.625% | -61.111% |
| Evolus Inc | -0.040% | -0.954% | -14.526% | -33.462% | -4.771% | -42.967% | -41.356% |
| Heron Therapeutics Inc. | -1.990% | 3.155% | 15.773% | -72.386% | -61.257% | -69.171% | -95.838% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
Anika Therapeutics (ANIK) had its "buy" rating reaffirmed by B. Riley Financial, Inc..
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (ANIK) had its price target raised by Barrington Research from $16.00 to $17.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
News
Anika Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Anika Therapeutics Inc.? Here are five stocks we like better.
- Second-quarter performance strengthened: Revenue rose 16% year over year to $32.6 million, while gross
